1. Home
  2. LEXX vs ELEV Comparison

LEXX vs ELEV Comparison

Compare LEXX & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • ELEV
  • Stock Information
  • Founded
  • LEXX 2004
  • ELEV 2019
  • Country
  • LEXX Canada
  • ELEV United States
  • Employees
  • LEXX N/A
  • ELEV N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • ELEV Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEXX Health Care
  • ELEV Health Care
  • Exchange
  • LEXX Nasdaq
  • ELEV Nasdaq
  • Market Cap
  • LEXX 38.9M
  • ELEV 37.6M
  • IPO Year
  • LEXX N/A
  • ELEV 2021
  • Fundamental
  • Price
  • LEXX $2.23
  • ELEV $0.58
  • Analyst Decision
  • LEXX Strong Buy
  • ELEV Strong Buy
  • Analyst Count
  • LEXX 2
  • ELEV 5
  • Target Price
  • LEXX $11.00
  • ELEV $7.20
  • AVG Volume (30 Days)
  • LEXX 202.7K
  • ELEV 860.8K
  • Earning Date
  • LEXX 01-10-2025
  • ELEV 11-06-2024
  • Dividend Yield
  • LEXX N/A
  • ELEV N/A
  • EPS Growth
  • LEXX N/A
  • ELEV N/A
  • EPS
  • LEXX N/A
  • ELEV N/A
  • Revenue
  • LEXX $464,278.00
  • ELEV N/A
  • Revenue This Year
  • LEXX $20.39
  • ELEV N/A
  • Revenue Next Year
  • LEXX $113.25
  • ELEV N/A
  • P/E Ratio
  • LEXX N/A
  • ELEV N/A
  • Revenue Growth
  • LEXX 105.24
  • ELEV N/A
  • 52 Week Low
  • LEXX $1.20
  • ELEV $0.44
  • 52 Week High
  • LEXX $6.85
  • ELEV $5.83
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 47.23
  • ELEV 43.94
  • Support Level
  • LEXX $2.00
  • ELEV $0.60
  • Resistance Level
  • LEXX $2.54
  • ELEV $0.70
  • Average True Range (ATR)
  • LEXX 0.24
  • ELEV 0.08
  • MACD
  • LEXX -0.00
  • ELEV -0.01
  • Stochastic Oscillator
  • LEXX 27.06
  • ELEV 7.67

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About ELEV Elevation Oncology Inc. Common stock

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Share on Social Networks: